May 10 (Reuters) - A new version of a bill that would

restrict U.S. business with certain Chinese biotechnology

companies including WuXi AppTec and BGI would give U.S.

companies until 2032 to end work with the firms, extending the

amount of time to find new partners.

The latest Biosecure Act also adds WuXi Biologics ( WXIBF ) to a list

of biotech companies of concern, according to a copy seen by

Reuters. The other companies on the list are BGI, MGI, Complete

Genomics and WuXi AppTec.

The revised bill will be introduced on Friday and a U.S.

House of Representatives committee is expected to decide next

week whether to move the bill forward, according to a House

Committee on Oversight and Accountability spokesperson.

The committee markup, expected Wednesday, is a procedural

step in the process to the bill's possibly becoming law. A

similar Senate bill was approved by a committee there in March.

The bills are designed to keep Americans' personal health

and genetic information from foreign adversaries.

A spokesperson for WuXi Biologics ( WXIBF ) said they had not yet seen

the revised bill and could not comment. The other companies

listed did not immediately respond to requests for comment.

The latest bill "highlights a key vulnerability in our

global supply chain and importantly provides a reasonable

timeframe for companies to decouple their reliance on

China-based biomanufacturing," John Crowley, president of BIO,

an industry association, said in a statement.